Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
Activist investor Starboard accuses Pfizer of strong-arming former execs into backing CEO Bourla ahead of strategy meeting
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting with activist investor Starboard Value, Pfizer's former CEO and CFO publicly changed their tune after being threatened with litigation by Pfizer,
FDA, Pfizer and hemophilia B
On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...
Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
As the battle over Pfizer’s future continues, former executives said they would no longer support activist investor Starboard ...
Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...
Pfizer is facing a messy showdown this week after an outside bid to revive the company’s post-Covid share plunge took an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback